Advaxis Secures $23 Million Financing

Last week, Advaxis, Inc. (a clinical-stage biotechnology company developing cancer immunotherapies on its proprietary Lm-LLO platform technology), announced that a combined $23 million of purchase agreements was raised, worth approximately 3.1 million shares, at a price of $7.50 per share from several institutional investors. The investors include Adage Capital Management, L.P. Broadfin Capital LLC, Sectoral Asset Management, Cormorant Asset Management and …

Geographical risk of Dengue and clinical studies conducted by Sanofi Pasteur

Making Dengue the Next Vaccine-Preventable Disease

Each year, there are approximately 50 million Dengue infections and an estimated 500,000 individuals are hospitalized with Dengue haemorrhagic fever. There have been attempts to develop a Dengue vaccine since the 1940s, but due to the limited appreciation of its global disease burden and market value, the industry’s interest deteriorated in the 20th century.   In 2013, the WHO ranked …

Ebola Hemorrhagic Fever, www.CDC.gov

Looming Pressure on Pharma as the Spread of Ebola Continues

When will a vaccine become available for Ebola? Killing over 8,000 people in West Africa since last year and still spreading, the need for a prophylactic Ebola vaccine is becoming increasingly important. Companies are racing to bring a safe vaccine to market and with the current pace of the epidemic in Liberia, Sierra Leone and Guinea, the demand for Ebola …

Inovio Presents Phase II Clinical Efficacy Data at the 15th World Vaccine Congress

With the 15th World Vaccine Congress on 13 – 15 October in Brussels is just next month I conducted an interview to one of our key speakers, Dr. Niranjan Y. Sardesai (COO, Inovio Pharmaceuticals, Inc.) to give you further insight into his new exciting clinical data and current challenges in developing cancer DNA vaccines.  Dr. Sardesai has broad development and …

Exclusive vaccine delivery interview with Dr Chantal Pichon, University of Orleans and CNRS

The 15th World Vaccine Congress on 13 – 15 October in Brussels is just a few weeks away and I recently sat down with one of our key speakers, Dr Chantal Pichon (Professor, University of Orleans and CNRS Center for Molecular Biophysics) for a short interview. Dr Pichon will be discussing her research in Histidylated-based nanoparticles for mRNA vaccines delivery. …